Moreover, it stimulates further cytokine production and suppresses the effect of insulin-like growth factor 1 (IGF-1), disrupting the GH/IGF-1 axis, and linking sarcopenic obesity to MASLD [6,7,8] (Figure 2). This evidence concerns the gene GH1 and metabolic dysfunction-associated steatotic liver disease.